Please login to the form below
Bristol Myers Squibb
This page shows the latest Bristol Myers Squibb news and features for those working in and with pharma, biotech and healthcare.
Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer
This included approvals for not only Keytruda, but also Roche’s Tecentriq (atezolizumab) and Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in a number of cancer types.
Latest news
-
Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study
The positive second-line LBCL Yescarta results follow recently reported data showing success for Bristol Myers Squibb’s (BMS) rival CAR-T therapy Breyanzi in the same patient population and setting.
-
CHMP recommends eight new medicines for EU approval
The positive opinions include Bristol Myers Squibb’s CAR T therapy Abecma (idecabtagene vicleucel) as a potential new treatment for highly refractory multiple myeloma.
-
BMS’s oral AML therapy Onureg receives EU approval
The European Commission has granted Bristol Myers Squibb’s (BMS) Onureg a full marketing authorisation as maintenance therapy for adult patients with acute myeloid leukaemia (AML). . ... aggressive blood cancer,” said Noah Berkowitz, senior vice
-
BMS and Eisai to collaborate in deal worth up to $3.1bn
Bristol Myers Squibb (BMS) and Eisai have entered a strategic collaboration focused on the development of Eisai’s antibody drug conjugate (ADC) candidate MORAb-202. ... This global collaboration with Eisai is an important strategic fit for Bristol
-
J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
EHA). The data comes from the phase 3 MAIA trial, which evaluated Darzalex (daratumumab) plus Bristol Myers Squibb’s Revlimid (lenalidomide) and dexamethasone compared with Revlimid and dexamethasone alone in newly
Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study
CHMP recommends eight new medicines for EU approval
BMS’s oral AML therapy Onureg receives EU approval
J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
More from news
Approximately 177 fully matching, plus 937 partially matching documents found.
Latest Intelligence
-
The impact of cancer on mental health during COVID-19
In the UK, All.Can is funded by Bristol Myers Squibb (primary sponsor) and MSD (supporting sponsor). ... If you would like more information on All.Can UK, please visit: . Hubert Bland is Bristol Myers Squibb’s UK and Ireland Executive Medical Director.
-
Why female mentorship is so powerful in pharma
Catherine Owen(pictured) is Senior Vice President of Major Markets at Bristol Myers Squibb.
-
Keeping up with the developing regulatory requirements for gene and cell therapies
Bristol Myers Squibb and bluebird bio’s idecabtagene vicleucel CAR-T therapy further emphasise this point.
-
Sourcing R&D innovation: why pharma companies need to evolve their business models
and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and
-
Switzerland: a life sciences hub
Celgene, now a subsidiary of Bristol-Myers Squibb (BMS), recently built its second production plant in Couvet, followed by the construction of a third production site in Boudry (Neuchâtel), to produce
The impact of cancer on mental health during COVID-19
Why female mentorship is so powerful in pharma
Keeping up with the developing regulatory requirements for gene and cell therapies
Sourcing R&D innovation: why pharma companies need to evolve their business models
Switzerland: a life sciences hub
More from intelligence
Approximately 4 fully matching, plus 50 partially matching documents found.
Latest appointments
-
Genmab hires first chief operating officer
Anthony Mancini joins from Bristol-Myers Squibb. Biotech company Genmab has appointed Anthony Mancini (pictured above) as executive vice president and to the newly created position of chief operating officer. ... Most recently, he led Bristol-Myers
-
Ex-BMS exec jumps to Gilead to lead research group
Gilead appoints Michael Quigley to lead research team. A former Bristol-Myers Squibb executive has jumped ship to Gilead, where he will head up the company’s research biology group.
-
New hires at FibroGen, Saniona and Turbine
Bristol-Myers Squibb.
-
New hires at Bristol-Myers Squibb, Acceleron and FerGene
The latest movers in pharma. Bristol-Myers Squibb. Bristol-Myers Squibb has announced changes to its leadership team, following the retirement of its current executive vice president of corporate affairs and
-
New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare
Roger Tomlins (pictured right), who joins Wilmington from Bristol-Myers Squibb, has worked in healthcare for over 16 years, in both the pharmaceutical industry and the NHS.
Genmab hires first chief operating officer
Ex-BMS exec jumps to Gilead to lead research group
New hires at FibroGen, Saniona and Turbine
New hires at Bristol-Myers Squibb, Acceleron and FerGene
New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare
More from appointments
Approximately 10 fully matching, plus 105 partially matching documents found.
Latest from PMHub
-
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
In contrast to many existing treatments for more difficult-to-control forms of psoriasis which are intravenous, TYK2 inhibitors– like Bristol Myers Squibb’s deucravacitinib (BMS-986165) –are being trialed as
-
Clinical trials and the diversity principle
In August, Bristol Myers Squibb announced it was committing $300m to tackle diversity in clinical trials, saying ‘COVID-19 has exposed the severity of social and health disparities in the US
-
July 2020: diversity and inclusion in clinical trials round-up
With this in mind, Stand Up To Cancer announced a new $5 million grant from Bristol Myers Squibb to fund research and education efforts to help improve health equality among underserved
-
Lucid Group are shortlisted in three categories for Communiqué 2020
Masterclass | NVAF-related Stroke Prevention in the UK: A Practical Perspective for Bristol-Myers Squibb/Pfizer Alliance.
-
Mergers and acquisitions: agents for change
Getting the best from your agency in a disruptive time. Multi-billion dollar mergers and acquisitions have always created headlines in pharma news, and it’s fair to say that the pharmaceutical industry probably experiences more of this type of
July 2020: diversity and inclusion in clinical trials round-up
Mergers and acquisitions: agents for change
More from PMHub
Approximately 3 fully matching, plus 7 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
-
Digital account director
-
Competitive
- FREELANCE (Outside IR35) Opportunities for this week below!!!
-
Superb Day Rate
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Client Services Director +, Remote or London – Leadership Opport...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital project manager
-
Competitive
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
-
Digital strategist
-
Competitive
-
Events Executive
-
Depending on Experience
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Israel study suggests Pfizer/BioNTech vaccine is less effective against Delta variant
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- bluebird bio to restart marketing of Zynteglo in EU after previous suspension
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
- J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
- Biogen and Ionis post ‘encouraging’ early results for Alzheimer’s disease candidate
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- #DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- Bayer’s BlueRock Therapeutics gains FDA fast track for Parkinson’s disease cell therapy
- Eylea set to challenge Lucentis in UK after NICE recommendation
- The future of office working designed with our people in mind: ‘Work Where You Work Best’, an Evoke KYNE model
- BioNTech to use mRNA technology to develop a ‘highly effective’ malaria vaccine
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- #DemandDiversity: Why cultural safety is an important step towards achieving diversity in clinical trials
- In our recent Demand Diversity research, a Black American participant said, “I wish people were more educated. Doctors are supposed to treat everyone the same, not have favourites. They need...
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
- The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
- Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
